Skip to main content
GENFIT logo

GENFIT — Investor Relations & Filings

Ticker · GNFT ISIN · FR0004163111 LEI · 969500XPWN2DMZQA5X73 PA Professional, scientific and technical activities
Open in API
Filings indexed 681 across all filing types
Latest filing 2016-10-03 Regulatory Filings
Country FR France
Listing PA GNFT

About GENFIT

https://www.genfit.com

GENFIT is a biopharmaceutical company dedicated to developing therapeutic and diagnostic solutions for patients with rare and severe liver diseases characterized by high unmet medical needs. The company's primary focus is on Acute-on-Chronic Liver Failure (ACLF) and its associated conditions, such as acute decompensation (AD) and hepatic encephalopathy (HE). Leveraging a scientific heritage of over two decades, GENFIT is a pioneer in liver disease research and development, aiming to improve the lives of patients with these life-threatening conditions.

Recent filings

Filing Released Lang Actions
2016.10.03 CP GENFIT AASLD & NASHTAG
Regulatory Filings Classification · 95% confidence The document is a press release dated October 3, 2016, announcing GENFIT's participation and data presentation at upcoming medical conferences (AASLD and NASH-TAG). It details specific abstracts to be presented and mentions future announcements. This type of communication, which announces corporate news, clinical trial updates, and participation in industry events, is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is not a full financial report (10-K, IR), a transcript (CT), or a specific management discussion (MDA), and it serves as an initial announcement of corporate activity/data presentation, 'ER' (Earnings Release) is the closest fit for a significant corporate update, although 'RNS' (Regulatory Filings) is also plausible. Given the focus on presenting new data and conference participation, it functions as a corporate news announcement, which often overlaps with ER content when not tied to a formal quarterly filing period. However, since it is a general corporate announcement about scientific data presentation and conference participation, and not explicitly tied to quarterly financial results (though it mentions Phase 2 data analysis), 'RNS' (Regulatory Filings) serves as a strong general category for non-standard, material corporate news releases. Given the context of financial reporting databases, this is a material corporate event announcement. I will classify it as 'RNS' as it is a general regulatory announcement about scientific progress and conference presence, which doesn't fit the specific financial report types.
2016-10-03 French
2016.09.27 CP GENFIT PBC
Regulatory Filings Classification · 96% confidence The document is explicitly titled "COMMUNIQUÉ DE PRESSE" (Press Release) multiple times. It announces a strategic business and clinical development update: GENFIT initiating an Investigational New Drug (IND) application for elafibranor in a new indication (PBC) and launching a Phase 2 trial. This type of announcement, detailing clinical progress, regulatory submissions, and strategic business moves, is characteristic of an Earnings Release (ER) or a general corporate announcement. Since it is a detailed announcement of clinical/regulatory progress rather than just financial highlights (ER) or a transcript (CT), it fits best under a general corporate/regulatory announcement category. Given the options, it is a significant corporate update that doesn't fit the specific financial report types (10-K, IR, AR) or specific transaction types (CAP, DIV, POS). It is a high-level announcement about drug development progress. While it could be argued as an 'ER' if it were tied to a quarterly period, the focus here is purely on R&D milestones and regulatory filings (IND submission). Since it is a formal announcement of a major corporate/clinical event, and not a full report, 'Regulatory Filings' (RNS) serves as the best general category for significant, non-standardized corporate news, or potentially 'Capital/Financing Update' (CAP) if the IND filing itself was the main focus, but the content is primarily clinical development news. However, looking closely at the definitions, 'ER' is for initial financial results highlights. This is a clinical/regulatory milestone announcement. Since it is a formal press release announcing a major step (IND filing and Phase 2 launch), it is a significant corporate communication. Given the lack of a specific 'Clinical Development Update' code, 'RNS' (Regulatory Filings - general regulatory announcements) is the most appropriate fallback for a press release detailing regulatory submissions and trial initiation, as it is a formal communication to the market about a regulatory step.
2016-09-27 French
2016.09.27 PR GENFIT PBC
Regulatory Filings Classification · 95% confidence The document is explicitly titled '# PRESS RELEASE' and contains language typical of an initial announcement regarding corporate or clinical development news ('GENFIT is Filing for IND Submission...', 'today announced that it is filing an IND submission...'). It details the initiation of a Phase 2 study and the filing of an Investigational New Drug (IND) application. This is not a comprehensive annual report (10-K), an interim report (IR), or a transcript (CT). It is a high-level announcement of a significant operational/clinical event, which aligns best with an Earnings Release (ER) if it were quarterly results, but since it is a specific clinical/regulatory update, it functions as a general press release announcing a key development. Given the options, this type of announcement, which is not a formal financial report, dividend notice, or management change, often falls under the general 'Regulatory Filings' (RNS) category if it doesn't fit elsewhere, or sometimes an 'Earnings Release' (ER) if it's the primary way news is disseminated. However, since it is a press release announcing a regulatory filing (IND) and the start of a trial, and not a financial results summary, 'RNS' (Regulatory Filings - general regulatory announcements) is the most appropriate fallback, although 'ER' is often used for major operational updates too. Given the focus on IND filing and trial launch, it is a significant corporate announcement, but not a standard financial report. I will classify it as RNS as it is a general regulatory/corporate announcement that doesn't fit the specific financial report codes.
2016-09-27 English
GENFIT Half year Report as of June 30, 2016
Interim / Quarterly Report Classification · 100% confidence The document is titled 'HALF-YEAR FINANCIAL REPORT' and covers the period ending June 30, 2016. It contains detailed sections on the company's overview, research programs, and key events, and explicitly references the inclusion of 'Half-year financial statements' and 'Statutory auditors' limited review report'. This meets the criteria for an Interim/Quarterly Report (IR) as it provides substantive financial analysis and reporting for a period shorter than a full fiscal year. H2 2016
2016-09-26 English
GENFIT Rapport Financier Semestriel au 30.06.2016
Interim / Quarterly Report Classification · 100% confidence The document is a 'Rapport Financier Semestriel' (Half-Year Financial Report) for the period ending June 30, 2016. It contains detailed financial statements, activity reports, and audit information, which fits the definition of an Interim/Quarterly Report (IR). It is not an announcement of a report, but the report itself, and it contains substantive financial and operational data. H2 2016
2016-09-26 French
160923_CP_GENFIT RORgt
Regulatory Filings Classification · 95% confidence The document is explicitly titled and formatted as a "COMMUNIQUÉ DE PRESSE" (Press Release). It announces a significant scientific and pipeline development: the identification of RORγt inverse agonists ready for pre-IND regulatory studies. This type of announcement, detailing scientific progress, pipeline expansion, and strategic updates, is characteristic of an Earnings Release (ER) or a general corporate/regulatory announcement. Since it is not a full financial report (10-K, IR), a transcript (CT), or a specific regulatory filing form, and it serves to disseminate key business news to the public and investors, the most appropriate classification is Earnings Release (ER), as these often include operational and pipeline milestones alongside financial highlights, or Regulatory Filing (RNS) as a general announcement. Given the focus on a major R&D milestone and the press release format, ER is a strong candidate, but RNS is the safest fallback for non-standard announcements. However, many companies use press releases for major pipeline updates that are not tied to quarterly results. Since the document is a formal announcement of a scientific breakthrough and pipeline advancement, and it is not a standard financial report, it fits best under the general category for corporate announcements that aren't strictly financial results (ER) or specific regulatory forms. Given the options, and recognizing this is a major corporate update disseminated via press release, I will classify it as a Regulatory Filing (RNS) as it is a general, non-standard filing type, although it shares characteristics with an ER. Upon review, the content is purely scientific/pipeline news, not financial results, making RNS the better fit than ER.
2016-09-23 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.